Ab­bott and Big­foot to de­velop di­a­betes tech­nolo­gies in US

BioSpectrum (Asia) - - World News -

Ab­bott has signed an agree­ment to in­te­grate its FreeStyle Li­bre glu­cose sens­ing tech­nol­ogy with Big­foot Biomed­i­cal’s in­sulin de­liv­ery so­lu­tions to de­velop and com­mer­cialise di­a­betes man­age­ment sys­tems in the US. Un­der the agree­ment, Big­foot will use the glu­cose sens­ing tech­nol­ogy to de­velop per­son­alised, user­friendly sys­tems for op­ti­mised in­sulin de­liv­ery and bet­ter di­a­betes man­age­ment.

The firm will ad­di­tion­ally de­velop sys­tems for auto-titra­tion of its con­nected in­sulin in­jec­tion de­vices and for au­to­mated de­liv­ery with its in­sulin in­fu­sion plat­form.

Big­foot is cur­rently working on in­jec­tion and in­fu­sion pump­based in­sulin de­liv­ery sys­tems that em­ploy In­ter­net of Things (IoT) con­nec­tiv­ity, smart­phone tech­nol­ogy, and ma­chine learn­ing to au­to­mat­i­cally ad­just in­sulin de­liv­ery or dos­ing for op­ti­mal glu­cose range.

Ini­tially launched in 2014 in Europe, the FreeStyle Li­bre sys­tem is cur­rently avail­able in more than 35 coun­tries. A clin­i­cal trial in­cor­po­rat­ing the glu­cose sens­ing tech­nol­ogy is ex­pected to be con­ducted next year by Big­foot in the US.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.